End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.6 CNY | +0.90% | -0.30% | +12.41% |
May. 15 | Nanhua Futures CFO Steps Down | MT |
Apr. 29 | LBX Pharmacy Chain Joint Stock Company Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 65% by 2026.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.79 for the current period. Therefore, the company is undervalued.
- The company has a low valuation given the cash flows generated by its activity.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.41% | 2.71B | C+ | ||
-11.83% | 2.97B | D- | ||
-28.03% | 2.88B | D | ||
+12.79% | 2.81B | - | ||
-0.84% | 1.91B | - | ||
+9.79% | 1.37B | - | - | |
-22.17% | 941M | - | ||
-36.96% | 716M | - | - | |
-0.53% | 453M | - | D+ | |
+9.57% | 413M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603883 Stock
- Ratings LBX Pharmacy Chain